Oramed Pharmaceuticals is waiting on approval from the FDA after its new insulin pill to treat type two diabetes had successful results in its phase two trial. Oramed Pharmaceuticals CEO Nadav Kidron joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss on The First Trade.
These three low-volatility, dividend-growth stocks offer the potential to rebound while trading near decade-low valuations.
The tallest building in Fort Worth, Texas, has been bought by a bank for $12.3 million, three years after it sold $137.5 million. Burnett Plaza has 40 stories and is 567 feet tall.
This historically flawless predictive tool has accurately foreshadowed what's to come for the U.S. economy since 1959.
The Oracle of Omaha keeps selling more stocks than he's buying. Here's what's on his shopping list.
Utility stocks are outperforming the broader markets. Here's a look at three top picks from analysts.
Starbucks is facing a number of challenges right now, and consumers may be opting for an up-and-coming chain as an alternative.
Dow Jones futures: Inflation reports loom with the stock market near record highs. Taiwan Semiconductor is in buy range.
This company also combines a powerful portfolio of both chips and software, not unlike what Nvidia is building.
Did lawmakers really pilfer Social Security's piggy bank? Here's the truth.